HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating for Allogene Therapeutics (NASDAQ:ALLO) and maintained a price target of $9.
October 30, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Allogene Therapeutics, maintaining a price target of $9. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. indicates a positive outlook for Allogene Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100